Stay updated with breaking news from Peter Kaiser. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
ABBV-RGX-314 continues to be well tolerated in 50 patients from dose levels 1 and 2 (Cohorts 1-3) with no drug-related serious adverse events Dose level 2...
The FDA approved a higher dosage of aflibercept (Eylea) for the treatment of age-related macular degeneration, macular edema, and diabetic retinopathy.
Regeneron Pharmaceuticals Inc. in Tarrytown recently announced that the U.S. Food and Drug Administration (FDA) has approved EYLEA HD (aflibercept) Injection 8 mg for the treatment of patients with wet age-related macular degeneration (wAMD), diabetic macular edema (DME) and diabetic retinopathy (DR). The recommended dose for EYLEA HD is 8 mg (0.07 mL of 114.3 […]
With approval, aflibercept 8 mg becomes the first and only treatment approved in wAMD and DME for immediate dosing at 8-week and up to 16-week intervals following 3 initial monthly doses.
19.08.2023 - Approval based on the pivotal PULSAR and PHOTON trials in which EYLEA HD demonstrated clinically equivalent vision gains to EYLEA (aflibercept) Injection 2 mg that were maintained with fewer injections First and only treatment approved in wAMD and ... Seite 1